Company profile AVIR
After 39 days of this quarter the interest is at 17.0. Based on that we can calculate that during remaining 52 days it will total up to 40.0. Atea Pharmaceuticals expected interest is significantly higher compared to previous quarter (+42.9%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 17 inf% QoQ | 32 88.2% QoQ | 58 81.2% QoQ |
| 2020 | 0 -100.0% QoQ | 68 300.0% YoY inf% QoQ | 28 -12.5% YoY -58.8% QoQ | 124 113.8% YoY 342.9% QoQ |
| 2021 | 115 inf% YoY -7.3% QoQ | 140 105.9% YoY 21.7% QoQ | 170 507.1% YoY 21.4% QoQ | 239 92.7% YoY 40.6% QoQ |
| 2022 | 58 -49.6% YoY -75.7% QoQ | 63 -55.0% YoY 8.6% QoQ | 42 -75.3% YoY -33.3% QoQ | 11 -95.4% YoY -73.8% QoQ |
| 2023 | 66 13.8% YoY 500.0% QoQ | 77 22.2% YoY 16.7% QoQ | 17 -59.5% YoY -77.9% QoQ | 28 154.5% YoY 64.7% QoQ |
| 2024 | 17 -74.2% YoY -39.3% QoQ | - | - | - |
The average 5 years interest of Atea Pharmaceuticals was 5.25 per week. The last year interest of Atea Pharmaceuticals compared to the last 5 years has changed by -33.33%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 69.9%.
There is not enough data for AT-527 COVID-19 Treatment to provide analysis
There is not enough data for AT-527 COVID-19 Treatment to provide correlation calculation
There is not enough data for AT-527 COVID-19 Treatment to provide analysis
There is not enough data for AT-752 Dengue Treatment to provide analysis
There is not enough data for AT-752 Dengue Treatment to provide correlation calculation
There is not enough data for AT-752 Dengue Treatment to provide analysis
There is not enough data for AT-281 Antiviral Treatment to provide analysis
There is not enough data for AT-281 Antiviral Treatment to provide correlation calculation
There is not enough data for AT-281 Antiviral Treatment to provide analysis
There is not enough data for Ruzasvir HCV Treatment to provide analysis
There is not enough data for Ruzasvir HCV Treatment to provide correlation calculation
There is not enough data for Ruzasvir HCV Treatment to provide analysis
There is not enough data for Atea Pharmaceuticals Clinical Trials to provide analysis
There is not enough data for Atea Pharmaceuticals Clinical Trials to provide correlation calculation
There is not enough data for Atea Pharmaceuticals Clinical Trials to provide analysis
After 39 days of this quarter the interest is at 9.0. Based on that we can calculate that during remaining 52 days it will total up to 21.0. Atea Pharmaceuticals Stock expected interest is significantly lower compared to same quarter last year (-75.9%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 26 inf% QoQ | 100 284.6% QoQ | 55 -45.0% QoQ |
| 2020 | 0 -100.0% QoQ | 30 15.4% YoY inf% QoQ | 32 -68.0% YoY 6.7% QoQ | 72 30.9% YoY 125.0% QoQ |
| 2021 | 84 inf% YoY 16.7% QoQ | 130 333.3% YoY 54.8% QoQ | 195 509.4% YoY 50.0% QoQ | 185 156.9% YoY -5.1% QoQ |
| 2022 | 20 -76.2% YoY -89.2% QoQ | 51 -60.8% YoY 155.0% QoQ | 11 -94.4% YoY -78.4% QoQ | 29 -84.3% YoY 163.6% QoQ |
| 2023 | 87 335.0% YoY 200.0% QoQ | 47 -7.8% YoY -46.0% QoQ | 20 81.8% YoY -57.4% QoQ | 33 13.8% YoY 65.0% QoQ |
| 2024 | 9 -89.7% YoY -72.7% QoQ | - | - | - |
The average 5 years interest of Atea Pharmaceuticals Stock was 4.66 per week. The last year interest of Atea Pharmaceuticals Stock compared to the last 5 years has changed by -39.7%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -19.25%.
After 39 days of this quarter the interest is at 88.0. Based on that we can calculate that during remaining 52 days it will total up to 205.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 76 | 22 -71.1% QoQ | 41 86.4% QoQ | 129 214.6% QoQ |
| 2020 | 0 -100.0% YoY -100.0% QoQ | 62 181.8% YoY inf% QoQ | 112 173.2% YoY 80.6% QoQ | 41 -68.2% YoY -63.4% QoQ |
| 2021 | 121 inf% YoY 195.1% QoQ | 65 4.8% YoY -46.3% QoQ | 66 -41.1% YoY 1.5% QoQ | 70 70.7% YoY 6.1% QoQ |
| 2022 | 91 -24.8% YoY 30.0% QoQ | 56 -13.8% YoY -38.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 25 -64.3% YoY inf% QoQ |
| 2023 | 147 61.5% YoY 488.0% QoQ | 45 -19.6% YoY -69.4% QoQ | 65 inf% YoY 44.4% QoQ | 218 772.0% YoY 235.4% QoQ |
| 2024 | 88 -40.1% YoY -59.6% QoQ | - | - | - |
The average 5 years interest of Atea Pharmaceuticals News was 5.9 per week. The last year interest of Atea Pharmaceuticals News compared to the last 5 years has changed by 60.68%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 84.08%.
There is not enough data for Atea Pharmaceuticals Boston to provide analysis
There is not enough data for Atea Pharmaceuticals Boston to provide correlation calculation
There is not enough data for Atea Pharmaceuticals Boston to provide analysis
There is not enough data for Atea Pharmaceuticals -stock -company to provide analysis
There is not enough data for Atea Pharmaceuticals -stock -company to provide correlation calculation
There is not enough data for Atea Pharmaceuticals -stock -company to provide analysis